Glaxosmithkline PLC, Director, 10% Owner at Turning Point Therapeutics, Inc. (TPTX), bought 1,445,730 shares at $18.00 ($5.8M) on 2019-04-22, disclosed to the SEC on 2019-04-24.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,120,730 | $0 | 0.0% |
| 2 | $18.00 | 325,000 | $5.8M | 100.0% |
| Total | $4.05 avg | 1,445,730 | $5.8M | 100% |
| Filing → |
| DBTX | BUY | 2021-02-19 | $2.7M | — | Filing → |
| BCYC | SELL | 2020-09-18 | $151K | — | Filing → |
| GNCA | BUY | 2020-07-30 | $2.8M | — | Filing → |